logo
Twitter
Discord
Email
logo
DBV Technologies S.A.

DBV Technologies S.A.

NASDAQ•DBVT
CEO: Mr. Daniel Tassé
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-10-22
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Contact Information
177-181 Avenue Pierre Brossolette, Montrouge, 92120, France
33-1-55-42-78-78
www.dbv-technologies.com
Market Cap
$497.09M
P/E (TTM)
-3.3
38.2
Dividend Yield
--
52W High
$26.19
52W Low
$3.80
52W Range
76%
Rank56Top 81.7%
2.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00-100.00%
4-Quarter Trend

EPS

-$1.60+0.00%
4-Quarter Trend

FCF

-$32.55M+42.44%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Financing Bolsters Cash Position Cash and equivalents reached $69.8M, up from $32.5M year-end 2024, following $125.5M gross proceeds received in April 2025.
Operating Income Shows Strength Nine months operating income was $5.0M, a 37% increase, primarily due to $1.4M higher Research Tax Credit recognized.
Financing Activities Provided Capital Cash flow provided by financing activities totaled $117.1M for nine months, reversing prior period usage due to capital raise completion.
Equity Position Significantly Improved Total Shareholders' Equity grew to $52.9M as of September 30, 2025, substantially increasing from $27.4M at year-end 2024.

Risk Factors

Net Loss Widens Operationally Nine months net loss increased 12% to $(102.1M) compared to prior year, driven by increased R&D investment costs.
R&D Expenses Significantly Increased Research and Development expenses rose 19.0% to $83.8M for nine months supporting COMFORT Toddlers and VITESSE trials.
Liquidity Raises Going Concern Cash sufficient only until Q3 2026; substantial doubt remains about continuing operations without securing necessary future financing.
Potential Share Dilution Risk Financing structure carries risk of up to 73.7% maximal dilution if all associated warrants from March 2025 offering are exercised.

Outlook

Viaskin Peanut BLA (4-7) Plan to submit BLA for older children in H1 2026, potentially accelerating product launch by approximately one year, subject to FDA approval.
VITESSE Topline Results Anticipated Anticipate receiving topline results for the Phase 3 VITESSE study in children ages 4-7 years in the fourth quarter of 2025.
Toddler Safety Study Progressing COMFORT Toddlers supplemental safety study initiated June 2025 to generate data supporting Accelerated Approval BLA pathway for 1-3 year olds.
Future Capital Needs Pursued Management actively pursuing additional ATM sales and strategic transactions to fund operations beyond estimated cash runway into Q3 2026.

Peer Comparison

Revenue (TTM)

Amarin Corporation plcAMRN
$225.62M
-6.7%
Cellectis S.A.CLLS
$75.27M
+158.9%
ADC Therapeutics SAADCT
$75.21M
+6.4%

Gross Margin (Latest Quarter)

Korro Bio, Inc.KRRO
100.0%
+0.0pp
Cellectis S.A.CLLS
93.3%
+10.5pp
ADC Therapeutics SAADCT
92.7%
-2.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RAPT$580.47M-9.0-61.8%1.6%
DBVT$497.09M-3.3-295.2%0.0%
ENGN$476.63M-7.3-31.1%14.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Apr 10, 2026
|
EPS:-$1.30
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 28, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-1.60+0.0%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 29, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-1.70+0.0%
    N/A

  • Form 10-K/A - FY 2024

    Period End: Dec 31, 2024|Filed: May 14, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-5.90-55.3%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: Apr 30, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-1.30-7.1%
    N/A

  • Form 10-K/A - FY 2024

    Period End: Dec 31, 2024|Filed: Apr 28, 2025|Refer to amended data

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Apr 11, 2025|Refer to amended data

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $1.07M-55.3%
    |
    EPS: $-1.60+88.2%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 30, 2024|
    Revenue: $1.16M-49.3%
    |
    EPS: $-1.70+30.8%
    Meet